← Pacira BioSciences, Inc. PCRX
Market Price
$23.00
Market Cap
$912.08M
P/E Ratio
143.75
Revenue (FY 2025)
↓-48.0% YoY
$726.41M
3-Yr CAGR: 2.9%
Net Income
↑107.1% YoY
$7.03M
Net Margin: 1.0%
Free Cash Flow
↓-23.5% YoY
$136.66M
FCF Yield: 14.98%
EPS (Diluted)
↑107.4% YoY
$0.16
Basic: $0.16
Return on Equity
Efficiency
1.0%
ROA: 21.6%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (PCRX)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $276.4M | — | $166.3M | $-37.9M | — | $-1.02 | — | $33.5M | $8.7M | — |
| FY 2017 | $286.6M | +3.7% | $198.7M | $-42.6M | -12.3% | $-1.07 | -4.9% | $17.8M | $-1.5M | -116.9% |
| FY 2018 | $332.4M | +16.0% | $245.6M | $-0.5M | +98.9% | $-0.01 | +99.1% | $48.9M | $34.4M | +2,419.8% |
| FY 2019 | $418.9M | +26.0% | $312.2M | $-11.0M | -2,238.9% | $-0.27 | -2,600.0% | $70.5M | $60.4M | +75.7% |
| FY 2020 | $426.6M | +1.8% | $309.3M | $145.5M | +1,421.0% | $3.33 | +1,333.3% | $77.0M | $39.2M | -35.0% |
| FY 2021 | $539.0M | +26.3% | $398.7M | $42.0M | -71.2% | $0.92 | -72.4% | $125.7M | $79.9M | +103.5% |
| FY 2022 | $666.8M | +23.7% | $467.5M | $15.9M | -62.1% | $0.34 | -63.0% | $145.3M | $115.2M | +44.3% |
| FY 2023 | $675.0M | +1.2% | $490.3M | $42.0M | +163.7% | $0.89 | +161.8% | $154.6M | $139.5M | +21.1% |
| FY 2024 | $1,398.2M | +107.1% | $1,227.7M | $-99.6M | -337.3% | $-2.15 | -341.6% | $189.4M | $178.8M | +28.1% |
| FY 2025 | $726.4M | -48.0% | $576.7M | $7.0M | +107.1% | $0.16 | +107.4% | $152.0M | $136.7M | -23.5% |
Valuation
Market Price
$23.00
Market Cap
$912.08M
Enterprise Value
$1.13B
P/E Ratio
143.75
P/B Ratio
1.31
FCF Yield
14.98%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
79.39%
Operating Margin
2.64%
Net Margin
0.97%
Return on Equity (ROE)
1.01%
Return on Assets (ROA)
21.56%
Asset Turnover
22.27x
Revenue 3-Yr CAGR
2.89%
Financial Health & Liquidity
Current Ratio
0.34
Cash Ratio
1.66
Debt / Equity
0.537
Debt / Assets
11.411
Cash & Equivalents
$158.54M
Total Debt
$372.19M
Book Value / Share
$17.61
Cash Flow Efficiency
Operating Cash Flow
$151.99M
Capital Expenditures (CapEx)
$15.33M
Free Cash Flow
$136.66M
OCF / Revenue
20.92%
FCF / Revenue
18.81%
FCF 3-Yr CAGR
5.86%
Per Share Metrics
EPS (Diluted)
$0.16
EPS (Basic)
$0.16
Dividends / Share
N/A
Book Value / Share
$17.61
EPS YoY Growth
107.44%
Balance Sheet (FY 2025)
Total Assets
$32.62M
Total Liabilities
$95.60M
Stockholders' Equity
$693.11M
Current Assets
$32.62M
Current Liabilities
$95.60M